Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Collegium Pharmaceutical, Inc (COLL)  
$36.42 0.58 (1.62%) as of 4:30 Fri 4/26


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 41,504,000
Market Cap: 1.51(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $21.06 - $40.91
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  625
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Collegium Pharmaceutical is a pharmaceutical company. Co.'s portfolio includes: Xtampza ER, Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol. Xtampza ER was approved by the U.S. Food and Drug Administration for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 10,995 133,280 276,351 867,449
Total Sell Value $400,850 $4,028,847 $7,154,366 $20,637,629
Total People Sold 2 4 4 6
Total Sell Transactions 2 8 13 39
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 391
  Page 1 of 16  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Smith Thomas B EVP and Chief Medical Officer   •       –      –    2024-02-29 4 S $36.76 $36,580 D/D (995) 63,409 2%     
   Dreyer Scott EVP & Chief Commercial Officer   •       –      –    2024-02-26 4 AS $36.38 $364,270 D/D (10,000) 138,918 -5%     
   Smith Thomas B EVP and Chief Medical Officer   •       –      –    2024-02-12 4 D $33.70 $107,806 D/D (3,199) 64,404     -
   Smith Thomas B EVP and Chief Medical Officer   •       –      –    2024-02-12 4 A $0.00 $0 D/D 35,423 67,603     -
   Ciaffoni Joseph President and CEO   •       •      –    2024-02-12 4 D $33.70 $4,342,818 D/D (128,867) 444,867     -
   Ciaffoni Joseph President and CEO   •       •      –    2024-02-12 4 A $0.00 $0 D/D 298,734 573,734     -
   Dreyer Scott EVP & Chief Commercial Officer   •       –      –    2024-02-12 4 D $33.70 $1,000,553 D/D (29,690) 148,918     -
   Dreyer Scott EVP & Chief Commercial Officer   •       –      –    2024-02-12 4 A $0.00 $0 D/D 67,286 178,608     -
   Kuhlmann Shirley R. EVP and General Counsel   •       –      –    2024-02-12 4 D $33.70 $1,070,177 D/D (31,756) 164,409     -
   Kuhlmann Shirley R. EVP and General Counsel   •       –      –    2024-02-12 4 A $0.00 $0 D/D 76,647 196,165     -
   Tupper Colleen EVP & Chief Financial Officer   •       –      –    2024-02-12 4 D $33.70 $887,018 D/D (26,321) 150,555     -
   Tupper Colleen EVP & Chief Financial Officer   •       –      –    2024-02-12 4 A $0.00 $0 D/D 71,456 176,876     -
   Dreyer Scott EVP & Chief Commercial Officer   •       –      –    2024-01-16 4 AS $32.28 $760,519 D/D (23,560) 111,322 8%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-21 4 AS $30.38 $132,377 D/D (4,357) 275,000 14%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-21 4 OE $21.34 $92,978 D/D 4,357 279,357     -
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-20 4 AS $30.40 $804,210 D/D (26,454) 275,000 17%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-20 4 OE $21.34 $564,528 D/D 26,454 301,454     -
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-19 4 AS $30.03 $435,942 D/D (14,516) 275,000 17%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-19 4 OE $21.34 $309,771 D/D 14,516 289,516     -
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-18 4 AS $30.04 $834,935 D/D (27,798) 275,000 16%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-12-18 4 OE $21.34 $593,209 D/D 27,798 302,798     -
   Kuhlmann Shirley R. EVP and General Counsel   •       –      –    2023-11-27 4 AS $25.78 $660,014 D/D (25,600) 119,518 52%     
   Kuhlmann Shirley R. EVP and General Counsel   •       –      –    2023-11-27 4 OE $15.90 $407,040 D/D 25,600 145,118     -
   Kuhlmann Shirley R. EVP and General Counsel   •       –      –    2023-06-26 4 AS $21.65 $390,633 D/D (17,984) 119,518 2%     
   Ciaffoni Joseph President and CEO   •       •      –    2023-06-02 4 AS $21.58 $675,424 D/D (31,272) 275,000 8%     
  391 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 16
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us